Patient Guide: Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 111 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06042478
Status: ACTIVE_NOT_RECRUITING
Condition: Chronic Spontaneous Urticaria
Phase: PHASE3

Where You Can Participate

This study is available at 111 locations across the country.

Top locations include:
  • • Caba, Buenos Aires
  • • Rosario, Santa Fe
  • • Bahia Blanca,
  • • And 108 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension. - Join Clinical Trial NCTNCT06042478

How to Join This Clinical Trial - NCTNCT06042478

Learn how to participate in this PHASE3 trial studying an investigational therapy for Chronic Spontaneous Urticaria. Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Chronic Spontaneous Urticaria. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Chronic Spontaneous Urticaria
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
ACTIVE_NOT_RECRUITING
Study Identifier
NCTNCT06042478 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 111 locations. Find a study site near you:

Clinical Research Site

Caba, Buenos Aires C1414AIF - Argentina

Status: Contact for availability

Clinical Research Site

Rosario, Santa Fe S2000DBS - Argentina

Status: Contact for availability

Clinical Research Site

Bahia Blanca, B8000JRB - Argentina

Status: Contact for availability

Clinical Research Site

Caba, C1012AAY - Argentina

Status: Contact for availability

Clinical Research Site

Capital Federal, C1023AAB - Argentina

Status: Contact for availability

Clinical Research Site

Mendoza, 5500 - Argentina

Status: Contact for availability

Clinical Research Site

Porto Alegre, RS 90560 030 - Brazil

Status: Contact for availability

Clinical Research Site

Alphaville Barueri, Sao Paulo 06454010 - Brazil

Status: Contact for availability

Clinical Research Site

Santo Andre, SP 09060-870 - Brazil

Status: Contact for availability

Clinical Research Site

Sorocaba, SP 18040-425 - Brazil

Status: Contact for availability

And 101 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Chronic Spontaneous Urticaria:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships